Vasopressin

1. Overview

Vasopressin — also known as arginine vasopressin (AVP) or antidiuretic hormone (ADH) — is an endogenous cyclic nonapeptide with the amino acid sequence Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH₂ and a molecular weight of 1084.23 Da. It features an intramolecular disulfide bridge between cysteine residues at positions 1 and 6, forming a six-membered ring with a three-residue C-terminal amidated tail. This structure differs from oxytocin by only two amino acids (phenylalanine at position 3 instead of isoleucine, and arginine at position 8 instead of leucine), yet these substitutions confer profoundly different receptor selectivity and physiological roles [8][14].

Vasopressin is synthesized primarily in magnocellular neurons of the supraoptic nucleus (SON) and paraventricular nucleus (PVN) of the hypothalamus. The AVP gene, located on chromosome 20p13 in humans, encodes a 164-amino acid preprohormone containing three functional domains: the vasopressin nonapeptide, neurophysin II (a 95-amino acid carrier protein), and a 39-amino acid C-terminal glycopeptide called copeptin. The preprohormone is packaged into neurosecretory granules and transported axonally through the hypothalamic-hypophyseal tract to the posterior pituitary (neurohypophysis), where sequential enzymatic cleavage during transport yields the mature hormone. Upon appropriate stimulation — primarily increased plasma osmolality detected by hypothalamic osmoreceptors or decreased blood volume detected by baroreceptors — vasopressin is released into the systemic circulation in equimolar amounts with neurophysin II and copeptin [5][24].

The biological effects of vasopressin are mediated through three G-protein coupled receptor subtypes: V1a (vascular smooth muscle, liver, platelets — vasoconstriction and platelet aggregation), V1b (anterior pituitary — ACTH secretion), and V2 (renal collecting duct — water reabsorption). This receptor diversity enables vasopressin to serve as a master integrator of cardiovascular, renal, endocrine, and behavioral homeostasis [4][18].

The pressor activity of posterior pituitary extracts was first demonstrated by Oliver and Schäfer in 1895. The antidiuretic properties were characterized independently by Verney in the 1940s. Vincent du Vigneaud at Cornell University Medical College determined the amino acid sequence and achieved the first total synthesis of vasopressin in 1954 — the first synthesis of any peptide hormone — earning him the Nobel Prize in Chemistry in 1955 "for his work on biochemically important sulphur compounds, especially for the first synthesis of a polypeptide hormone" [14][15].

Clinically, synthetic vasopressin is marketed as Vasostrict (IV) and has been FDA-approved for vasodilatory shock and diabetes insipidus. Its synthetic analogues — desmopressin (DDAVP) and terlipressin — have extended the therapeutic reach of the vasopressin system to conditions including nocturnal enuresis, hemophilia A, von Willebrand disease, hepatorenal syndrome, and variceal bleeding.

Molecular Weight

1084.23 Da

Sequence

Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH₂ (disulfide bridge Cys1–Cys6)

Half-life

10–20 minutes (IV)

Receptors

V1a (Gq — vasoconstriction), V1b (Gq — ACTH release), V2 (Gs — antidiuresis)

Routes Used

Intravenous infusion (clinical), intramuscular, subcutaneous

FDA Status

Approved for vasodilatory shock (Vasostrict) and diabetes insipidus (Pitressin)

Discovery

Pressor/antidiuretic activity identified by Oliver & Schäfer (1895); synthesized by Vincent du Vigneaud (1954; Nobel Prize in Chemistry, 1955)

2. Mechanism of Action

V1a Receptor — Vasoconstriction and Hemostasis

The V1a receptor (AVPR1A) is expressed on vascular smooth muscle cells, hepatocytes, platelets, myometrium, and multiple brain regions (lateral septum, bed nucleus of the stria terminalis, cortex). It couples to Gq/11 proteins, activating phospholipase C (PLC), which hydrolyzes PIP₂ to generate inositol 1,4,5-trisphosphate (IP₃) and diacylglycerol (DAG). IP₃ triggers calcium release from the sarcoplasmic reticulum, while DAG activates protein kinase C (PKC). The resulting rise in intracellular calcium activates calmodulin-dependent myosin light chain kinase (MLCK), phosphorylating myosin light chains and driving smooth muscle contraction. PKC additionally sensitizes the contractile apparatus by inhibiting myosin light chain phosphatase [4][17].

In the vasculature, V1a activation produces potent vasoconstriction, particularly in the splanchnic, cutaneous, and muscular vascular beds. In the liver, V1a signaling stimulates glycogenolysis and gluconeogenesis. On platelets, V1a receptor activation promotes aggregation and enhances the hemostatic response [4][18].

V1b Receptor — Neuroendocrine Regulation

The V1b receptor (AVPR1B, also called V3) is located primarily in corticotroph cells of the anterior pituitary, where it also couples to Gq/11-PLC signaling. V1b activation stimulates adrenocorticotropic hormone (ACTH) secretion, acting synergistically with corticotropin-releasing hormone (CRH) to amplify the hypothalamic-pituitary-adrenal (HPA) axis stress response. V1b receptors are also found in the pancreas (where they modulate insulin secretion), adrenal medulla, and brain (hippocampus, amygdala) [4].

V2 Receptor — Antidiuresis

The V2 receptor (AVPR2) is located on the basolateral membrane of principal cells in the renal collecting duct. It couples to Gs proteins, activating adenylyl cyclase and increasing intracellular cyclic AMP (cAMP). cAMP activates protein kinase A (PKA), which phosphorylates aquaporin-2 (AQP2) water channels at serine 256, triggering their translocation from intracellular storage vesicles to the apical plasma membrane. This insertion of AQP2 channels dramatically increases the water permeability of the collecting duct, allowing osmotic water reabsorption from the tubular lumen into the hypertonic medullary interstitium. Water exits basolaterally through constitutively expressed aquaporin-3 and aquaporin-4 channels. When vasopressin levels fall, AQP2 is internalized by clathrin-mediated endocytosis and recycled into intracellular vesicles [5][23].

Chronic vasopressin stimulation additionally increases AQP2 gene transcription via cAMP response element binding protein (CREB), further amplifying the antidiuretic response. V2 receptor activation on vascular endothelial cells also triggers release of von Willebrand factor (VWF) and Factor VIII from Weibel-Palade bodies, and promotes vasodilation via endothelial nitric oxide synthase (eNOS) activation — effects exploited therapeutically by desmopressin [10][17].

Additional Mechanisms in Shock States

In vasodilatory shock (including sepsis), vasopressin acts through multiple complementary mechanisms beyond V1a-mediated vasoconstriction: it blocks ATP-sensitive potassium channels (KATP) that are pathologically opened during shock, it potentiates the vasoconstrictive effects of catecholamines, and it inhibits excessive nitric oxide (NO) production via suppression of inducible nitric oxide synthase (iNOS). These mechanisms explain vasopressin's effectiveness when catecholamine-resistant vasodilation occurs [11][16][17].

3. Clinical Applications

Central Diabetes Insipidus

Evidence level: High (established indication)

Central (neurogenic) diabetes insipidus results from deficient vasopressin production or release by the hypothalamus/posterior pituitary due to surgery, trauma, tumors, infiltrative disease, or genetic mutations. Patients present with polyuria (up to 20 L/day), polydipsia, and dilute urine (osmolality <300 mOsm/kg). Treatment with exogenous vasopressin or, more commonly, desmopressin (DDAVP) replaces the missing hormone and concentrates urine via V2 receptor activation. Desmopressin is preferred for chronic management due to its V2 selectivity (1500-fold greater than V1a), longer duration of action (6–14 hours vs. 10–20 minutes for vasopressin), and freedom from vasoconstrictive side effects [5][8].

Vasodilatory Shock

Evidence level: High (FDA-approved)

Vasopressin (Vasostrict) is FDA-approved for the treatment of vasodilatory shock in adults who remain hypotensive despite adequate fluid resuscitation and catecholamine vasopressors. In septic shock specifically, up to one-third of patients develop relative vasopressin deficiency — plasma AVP levels that are inappropriately low for the degree of hypotension — contributing to catecholamine-refractory vasoplegia. Low-dose vasopressin infusion (0.01–0.04 U/min) restores vasomotor tone through V1a-mediated vasoconstriction while preserving renal blood flow via V2-mediated efferent arteriolar dilation [1][11][16].

The Surviving Sepsis Campaign guidelines recommend vasopressin (up to 0.03 U/min) as a second-line vasopressor added to norepinephrine when the target mean arterial pressure (MAP) cannot be achieved with norepinephrine alone [11].

Septic Shock — The VASST Trial

Evidence level: High (landmark multicenter RCT)

The Vasopressin and Septic Shock Trial (VASST), published in the New England Journal of Medicine in 2008 by Russell et al., was the definitive trial evaluating vasopressin in septic shock. This multicenter, double-blind RCT randomized 778 patients receiving norepinephrine to receive blinded infusions of either vasopressin (0.01–0.03 U/min) or additional norepinephrine (5–15 μg/min). The primary outcome of 28-day mortality showed no significant difference (35.4% vasopressin vs. 39.3% norepinephrine, P=0.26). However, a pre-specified subgroup of patients with less severe shock (norepinephrine requirement <15 μg/min at enrollment) showed a trend toward mortality benefit with vasopressin (26.5% vs. 35.7%, P=0.05). Vasopressin also demonstrated a significant catecholamine-sparing effect [1].

Cardiac Arrest

Evidence level: Moderate (historical use; removed from ACLS 2015)

Vasopressin was incorporated into the American Heart Association (AHA) ACLS algorithm in 2000 as an alternative to epinephrine in cardiac arrest, based on its superior coronary perfusion pressure in animal models and its longer half-life (10–20 minutes vs. 3–5 minutes). The recommended dose was 40 IU IV push as a single dose replacing the first or second dose of epinephrine. Wenzel et al. (2004) found that vasopressin plus epinephrine improved survival in the asystole subgroup (4.7% vs. 1.5%, P=0.04), though no overall benefit was demonstrated [2]. Subsequent meta-analyses confirmed no meaningful difference between vasopressin and epinephrine for survival to discharge, and vasopressin was removed from the ACLS algorithm in 2015.

Variceal Bleeding

Evidence level: Moderate (supplanted by terlipressin where available)

Vasopressin is the most potent splanchnic vasoconstrictor available, reducing portal venous inflow and portal pressure by constricting mesenteric arterioles and precapillary sphincters. For acute esophageal variceal hemorrhage, continuous IV infusion (0.2–0.4 U/min, up to 0.8 U/min) can arrest bleeding in up to 80% of cases. However, systemic vasoconstrictive side effects (cardiac ischemia, mesenteric ischemia, peripheral gangrene) necessitate concurrent IV nitroglycerin (40–400 μg/min) and limit treatment to 24 hours at maximal doses. Side effect-related withdrawal rates approach 25%. Terlipressin has largely replaced vasopressin for this indication due to its superior safety profile, V1a selectivity, and longer duration of action [19][25].

Nocturnal Enuresis

Evidence level: High (established indication for desmopressin)

Primary nocturnal enuresis in children is frequently associated with a failure of the normal nocturnal rise in vasopressin secretion, resulting in excessive nighttime urine production. Oral desmopressin (0.2–0.4 mg at bedtime) reduces wet nights by an average of 1.34 per week compared to placebo, with approximately 16–19% of children achieving full dryness during treatment. A Cochrane meta-analysis of 47 RCTs confirmed efficacy but noted high relapse rates after discontinuation. The intranasal formulation is no longer recommended for enuresis due to the risk of hyponatremic seizures; fluid restriction after the evening dose is essential [9].

Bleeding Disorders — Desmopressin

Evidence level: High (established indication)

Desmopressin (0.3 μg/kg IV) induces a rapid 2- to 5-fold increase in plasma von Willebrand factor (VWF) and Factor VIII (FVIII) within 30–60 minutes by activating V2 receptors on endothelial cells, which trigger cAMP-dependent exocytosis from Weibel-Palade bodies. This mechanism makes desmopressin the treatment of choice for type 1 von Willebrand disease and mild hemophilia A (FVIII levels >5%), both for acute bleeding episodes and pre-procedural prophylaxis [10].

4. Terlipressin — A Key Vasopressin Analogue

Terlipressin (triglycyl-lysine vasopressin) is a synthetic prodrug with twice the selectivity for V1a receptors compared to native vasopressin. Endopeptidases slowly cleave its N-terminal triglycyl moiety to yield the active metabolite lysine vasopressin, producing a sustained "slow-release" effect with a biological half-life of approximately 6 hours (compared to 10–20 minutes for vasopressin). This pharmacokinetic advantage allows intermittent bolus dosing rather than continuous infusion [19][25].

Terlipressin is approved in many countries for:

• Acute variceal bleeding: Reduces portal pressure via splanchnic vasoconstriction. Decreases failure of initial hemostasis by 34% and mortality by 34% compared to placebo. Considered first-line vasoactive therapy where available [19][25].

• Hepatorenal syndrome (HRS): The CONFIRM trial (2021) demonstrated that terlipressin plus albumin achieved verified HRS reversal in 32% of patients vs. 17% with placebo plus albumin (P=0.006), leading to FDA approval of terlipressin (Terlivaz) in the US in 2022 for HRS with rapid reduction in kidney function. Terlipressin acts by constricting dilated splanchnic vessels, restoring effective arterial blood volume and improving renal perfusion [3][19].

5. Copeptin as a Biomarker

Copeptin, the 39-amino acid C-terminal fragment of the vasopressin prohormone, is released in equimolar amounts with AVP but is far more stable in vitro. Direct measurement of vasopressin is confounded by its pulsatile secretion, small molecular size, avid binding to platelets, rapid clearance (half-life 10–20 minutes), and degradation at room temperature. Copeptin overcomes all of these preanalytical challenges and has emerged as a reliable surrogate marker for AVP secretion [6][24].

Key clinical applications of copeptin measurement include:

• Differential diagnosis of polyuria-polydipsia syndromes: A copeptin-based diagnostic protocol (Fenske et al., 2018, NEJM) demonstrated 96.5% diagnostic accuracy for distinguishing central diabetes insipidus from primary polydipsia, significantly outperforming the traditional indirect water deprivation test (76.6% accuracy) [13].

• Cardiovascular risk stratification: Elevated copeptin independently predicts mortality in heart failure, acute myocardial infarction, and stroke. Combined with high-sensitivity troponin, copeptin enables rapid rule-out of AMI in emergency settings [6][21].

• Sepsis and critical illness: Copeptin is markedly elevated in hemorrhagic and septic shock, correlating with disease severity and serving as a prognostic marker [21].

6. Social Behavior and Neuroscience Research

Pair Bonding and the Prairie Vole Model

The socially monogamous prairie vole (Microtus ochrogaster) has been instrumental in elucidating vasopressin's role in social behavior. Prairie voles form lifelong pair bonds, display biparental care, and exhibit selective aggression toward strangers — behaviors largely absent in the closely related but promiscuous montane vole. Research by Young, Wang, and colleagues revealed that V1a receptor density in reward-related brain circuits (particularly the ventral pallidum) is dramatically higher in monogamous voles compared to promiscuous species. Viral vector-mediated overexpression of the V1a receptor in the ventral pallidum of promiscuous meadow voles was sufficient to induce partner preference formation [7][20].

The species difference in V1a receptor distribution is linked to a microsatellite polymorphism in the avpr1a gene promoter region. Longer microsatellite variants drive higher V1a receptor expression in reward regions, facilitating pair bond formation. In humans, AVPR1A promoter region polymorphisms have been associated with variation in partner bonding quality, autism risk, and altruistic behavior, though effect sizes are modest [7][20].

Social Recognition Memory

Vasopressin is critical for social recognition memory — the ability to identify and remember conspecifics. Central V1a receptor activation in the lateral septum facilitates social memory in rodents, while V1a receptor blockade impairs it. V1b knockout mice show deficits in social aggression and social memory. In the brain, vasopressin is released from sexually dimorphic pathways (the bed nucleus of the stria terminalis to the lateral septum is denser in males), suggesting sexually differentiated roles in social cognition [12][20].

Aggression and Anxiety

Vasopressin facilitates intermale aggression and modulates anxiety-related behaviors. Intracerebroventricular vasopressin increases aggressive behavior in hamsters and rats, while V1a receptor antagonists reduce it. The relationship with anxiety is complex: vasopressin can be anxiogenic or anxiolytic depending on the brain region, dose, and behavioral context [12].

7. Desmopressin — Pharmacological Comparison

Desmopressin (1-deamino-8-D-arginine vasopressin, DDAVP) incorporates two structural modifications from native vasopressin: (1) deamination of the N-terminal cysteine, which protects against aminopeptidase degradation and enhances antidiuretic potency, and (2) substitution of L-arginine with D-arginine at position 8, which confers resistance to endopeptidase cleavage and eliminates V1a receptor-mediated vasoconstriction. The result is a peptide with:

| Property | Vasopressin | Desmopressin | |---|---|---| | V2:V1a selectivity | ~1:1 | ~1500:1 | | Antidiuretic potency | 1× (reference) | ~2–3× | | Pressor activity | +++ | Negligible | | Half-life | 10–20 min | 6–14 h (oral ~2–3 h) | | Routes | IV, IM, SC | Oral, intranasal, IV, SC | | Factor VIII/VWF release | + | +++ |

Desmopressin is the treatment of choice for central diabetes insipidus (chronic management), nocturnal enuresis, type 1 von Willebrand disease, mild hemophilia A, and uremic bleeding [8][9][10].

8. Clinical Evidence Summary

9. Dosing in Research and Clinical Practice

The following table summarizes doses used in approved clinical indications and key research studies. Vasopressin dosing varies substantially across indications and must be titrated carefully given the narrow therapeutic window.

10. Safety and Side Effects

Cardiovascular Risks

The most significant safety concern with vasopressin is ischemia resulting from potent vasoconstriction via V1a receptors. At therapeutic and supratherapeutic doses, vasopressin can precipitate:

• Coronary ischemia and myocardial infarction: Vasopressin should be used with extreme caution in patients with coronary artery disease. Even small doses may provoke anginal pain, and large doses can cause myocardial infarction [17][26].
• Mesenteric ischemia: Splanchnic vasoconstriction, particularly during variceal bleeding therapy, can compromise intestinal perfusion.
• Digital and peripheral ischemia: Cutaneous vasoconstriction can cause skin necrosis, particularly when high-dose infusions extravasate or in patients with peripheral vascular disease.
• Decreased cardiac output and bradycardia: V1a-mediated afterload increase and coronary vasoconstriction can reduce cardiac performance.

Water Intoxication and Hyponatremia

Because vasopressin activates both V1a and V2 receptors, continuous infusions for vasodilatory shock or variceal bleeding can cause clinically significant antidiuresis, leading to dilutional hyponatremia and water intoxication. Symptoms range from headache and nausea to seizures, cerebral edema, coma, and death. Serum sodium must be monitored regularly during vasopressin infusions, and free water intake should be restricted. This risk is amplified with desmopressin, which has exclusive V2 activity: the intranasal formulation was withdrawn from the nocturnal enuresis indication due to reports of hyponatremic seizures in children who drank excessive fluids at bedtime [9][26].

Other Adverse Effects

• Arrhythmias: Tachyarrhythmias, bradycardia, and heart block have been reported.
• Gastrointestinal: Nausea, vomiting, abdominal cramping, and diarrhea are common, especially at higher doses.
• Hypertension: V1a-mediated vasoconstriction can cause dangerous blood pressure elevation.
• Allergic reactions: Rare anaphylaxis has been reported.
• Terlipressin-specific: Respiratory failure (due to pulmonary edema from fluid redistribution) was a notable adverse event in the CONFIRM trial, occurring in 11% of terlipressin patients vs. 2% with placebo [3].

Dosing Safety Principles

Vasopressin should be titrated to the lowest effective dose. For vasodilatory shock, increments of 0.005 U/min at 10–15 minute intervals are recommended. After 8 hours of hemodynamic stability without catecholamines, vasopressin should be tapered gradually (0.005 U/min per hour). Abrupt discontinuation risks rebound hypotension. Limited safety data exist for doses exceeding 0.1 U/min in post-cardiotomy shock or 0.07 U/min in septic shock [11].

11. Pharmacokinetics

Understanding vasopressin's pharmacokinetic profile is essential for optimizing its clinical use, particularly in critical care settings where precise titration determines the balance between therapeutic efficacy and ischemic complications.

Intravenous vasopressin. Following IV bolus administration, vasopressin distributes rapidly with a volume of distribution of approximately 140-200 mL/kg (roughly total body water). The plasma elimination half-life is 10-35 minutes, with most studies reporting 10-20 minutes in healthy adults. This short half-life reflects rapid enzymatic degradation by vasopressinases (cystine aminopeptidases) in the liver, kidney, and placenta (during pregnancy), as well as receptor-mediated endocytosis and degradation. Hepatic clearance accounts for approximately 50-60% of total clearance, with renal clearance contributing 20-30% through both glomerular filtration and tubular catabolism. Total metabolic clearance is approximately 2-4 mL/kg/min [16][17].

Continuous infusion pharmacokinetics. During continuous IV infusion at vasodilatory shock doses (0.01-0.04 U/min), steady-state plasma concentrations are achieved within 30-60 minutes (approximately 3-5 half-lives). At 0.03 U/min, steady-state plasma levels typically reach 30-100 pg/mL, compared to the normal physiological range of 1-5 pg/mL and the endogenous levels of 3-20 pg/mL seen in septic shock patients with relative vasopressin deficiency [11][16]. The dose-concentration relationship is approximately linear within the clinical dosing range.

Pharmacokinetics in critical illness. Septic shock profoundly alters vasopressin kinetics. In the early phase (0-24 hours), plasma AVP levels are appropriately elevated (20-100+ pg/mL), but in established septic shock, levels fall to inappropriately low values (approximately 3-10 pg/mL) -- a phenomenon termed relative vasopressin deficiency [11][16]. This depletion results from exhaustion of neurohypophyseal stores after sustained secretion, downregulation of hypothalamic synthesis, and possibly increased peripheral degradation. The VASST trial documented that exogenous vasopressin infusion at 0.01-0.03 U/min restores plasma concentrations to the 30-100 pg/mL range associated with hemodynamic improvement [1].

Desmopressin pharmacokinetics. Desmopressin exhibits dramatically different pharmacokinetics: the deamination at Cys1 and D-arginine at position 8 confer resistance to enzymatic degradation, extending the half-life to 75-120 minutes (IV), 2-3 hours (oral), and 3-8 hours (intranasal). Oral bioavailability is approximately 0.08-0.16% (requiring 100-200-fold higher doses), intranasal bioavailability is approximately 3-5%, and IV bioavailability is 100%. The prolonged duration of action (6-14 hours for antidiuretic effect) makes desmopressin suitable for chronic outpatient use [8][9].

Terlipressin pharmacokinetics. Terlipressin, the triglycyl-lysine prodrug, has a plasma half-life of approximately 6 hours (parent compound) due to slow enzymatic conversion to the active metabolite lysine vasopressin by tissue endopeptidases. This sustained release kinetics allows intermittent IV bolus dosing (1-2 mg every 4-6 hours) rather than continuous infusion, a practical advantage in the management of variceal bleeding and hepatorenal syndrome [19][25].

Copeptin as a pharmacokinetic surrogate. Direct measurement of endogenous vasopressin is technically challenging due to its short half-life, platelet binding, and preanalytical instability. Copeptin (C-terminal pro-AVP), released in equimolar amounts from the prohormone, has a substantially longer half-life and greater in vitro stability, making it the preferred biomarker for assessing endogenous AVP secretion [6][24].

12. Dose-Response Relationships

Vasopressin's dose-response relationships vary markedly across its clinical applications, reflecting the differential activation of V1a, V1b, and V2 receptors at different plasma concentrations.

Vasodilatory shock (0.01-0.04 U/min). The FDA-approved dose range for Vasostrict demonstrates a steep dose-response relationship for hemodynamic effects. At 0.01 U/min (the typical starting dose), modest vasoconstriction begins through V1a receptor engagement, producing a mean arterial pressure (MAP) increase of approximately 5-10 mmHg and enabling initial catecholamine sparing. At 0.03 U/min (the Surviving Sepsis Campaign recommended maximum as a second-line agent), robust vasoconstriction is established, with MAP increases of 10-20 mmHg and norepinephrine-equivalent doses often reducible by 40-65%. At 0.04 U/min (the FDA maximum), the risk of ischemic complications -- particularly mesenteric, digital, and cardiac ischemia -- increases substantially without proportional hemodynamic benefit, reflecting the narrow therapeutic index [1][11].

Septic shock -- the VASST dose-response. The VASST trial's pre-specified subgroup analysis revealed an important dose-response interaction: patients with less severe shock (requiring norepinephrine less than 15 mcg/min at enrollment) showed a potential mortality benefit with vasopressin (26.5% vs 35.7%, P=0.05), while patients with more severe shock showed no benefit. This suggests that vasopressin is most effective as an early adjunctive agent rather than a rescue therapy in refractory shock. The catecholamine-sparing effect allows norepinephrine dose reduction by a mean of 25-50% within the first 4-6 hours of vasopressin initiation [1][11].

Antidiuretic dose-response. V2 receptor-mediated antidiuresis is activated at plasma AVP concentrations as low as 1-2 pg/mL (threshold for antidiuretic effect), with maximal urine concentration achieved at approximately 5-10 pg/mL. This is well below the vasoconstrictive threshold (approximately 10-50 pg/mL via V1a), explaining how physiological AVP concentrations regulate water balance without causing hypertension. During vasopressin infusion for shock, the supratherapeutic V2 stimulation invariably produces significant antidiuresis, necessitating careful monitoring of serum sodium and free water restriction [5][16].

Variceal bleeding (0.2-0.8 U/min). The variceal bleeding dose range is 5-20-fold higher than the vasodilatory shock dose, reflecting the need for intense splanchnic vasoconstriction to reduce portal venous pressure. Portal pressure reduction of 20-30% is typically achieved at 0.4 U/min. At doses exceeding 0.4 U/min, the risk of cardiac ischemia, mesenteric ischemia, and peripheral gangrene increases significantly, requiring concurrent nitroglycerin infusion (40-400 mcg/min) to mitigate systemic vasoconstrictive toxicity [19][25].

Cardiac arrest (40 IU single dose). The cardiac arrest dose represents a massive pharmacological bolus (equivalent to approximately 26.7 U/min for the first minute if considering rapid distribution). At these concentrations, vasopressin produces intense generalized vasoconstriction that increases coronary and cerebral perfusion pressure during CPR. The rationale for this dose was based on animal studies showing superior coronary perfusion pressure compared to epinephrine [2].

13. Comparative Effectiveness

Vasopressin vs. Norepinephrine in Septic Shock

The VASST trial (2008, n=778) is the definitive comparative study. Low-dose vasopressin (0.01-0.03 U/min) added to norepinephrine showed no significant difference in 28-day mortality compared to norepinephrine alone (35.4% vs 39.3%, P=0.26). However, the pre-specified subgroup with less severe shock showed a trend toward benefit with vasopressin (26.5% vs 35.7%, P=0.05). The VANISH trial (2016, n=409) compared vasopressin versus norepinephrine as first-line vasopressor in septic shock and found no significant difference in kidney failure-free days or mortality, though vasopressin was associated with less need for renal replacement therapy [1].

Current Surviving Sepsis Campaign guidelines (2021) recommend vasopressin (up to 0.03 U/min) as a second-line vasopressor added to norepinephrine when MAP target cannot be achieved, or to reduce norepinephrine dose (weak recommendation, moderate-quality evidence). Norepinephrine remains the recommended first-line vasopressor [11].

The optimal threshold for vasopressin initiation in septic shock remains an active area of investigation. The VASSPR trial (Vasopressin for Septic Shock Pragmatic), a multicenter, open-label, cluster-randomized, multiple cluster-crossover pragmatic trial across 13 hospitals in Utah and Idaho, began enrollment in February 2024 and was designed to close enrollment in July 2025. VASSPR compares different thresholds for initiating vasopressin as a secondary vasopressor, with 28-day all-cause mortality as the primary outcome and renal replacement therapy-free days as a key secondary outcome. Results are anticipated in 2026.

Vasopressin vs. Desmopressin

| Feature | Vasopressin | Desmopressin (DDAVP) | |---|---|---| | V2:V1a selectivity | ~1:1 | ~1500:1 | | Half-life | 10-35 min (IV) | 75-120 min (IV); 6-14 h (effect) | | Pressor activity | +++ (potent) | Negligible | | Antidiuretic potency | 1x (reference) | 2-3x | | Factor VIII/VWF release | + (modest) | +++ (strong, sustained) | | Clinical use | Vasodilatory shock, DI (acute) | Chronic DI, enuresis, bleeding disorders | | Oral bioavailability | Not orally available | 0.08-0.16% (adequate at higher doses) | | Routes | IV, IM, SC | IV, SC, oral, intranasal, sublingual |

Desmopressin is preferred for all chronic indications (diabetes insipidus, nocturnal enuresis, bleeding disorders) due to its prolonged action, V2 selectivity (avoiding vasoconstrictive side effects), and availability in multiple formulations including oral and intranasal [8][9][10].

Vasopressin vs. Terlipressin

| Feature | Vasopressin | Terlipressin | |---|---|---| | Receptor selectivity | V1a = V1b = V2 | V1a-selective (2x vs vasopressin) | | Half-life | 10-35 min | ~6 hours (prodrug) | | Administration | Continuous infusion | Intermittent bolus (q4-6h) | | Variceal bleeding | Effective but more side effects | First-line where available; 34% reduced mortality vs placebo | | Hepatorenal syndrome | Not established | FDA-approved (CONFIRM: 32% vs 17% reversal) | | Septic shock | VASST data (second-line) | Limited data; TERLIVAP trial inconclusive | | Side effect burden | Higher (systemic V1a/V2) | Lower (V1a-selective, longer t1/2) |

Terlipressin has largely replaced vasopressin for variceal bleeding and is the only vasopressin analogue FDA-approved for hepatorenal syndrome (CONFIRM trial: 32% reversal vs 17% placebo, P=0.006) [3][19][25].

Vasopressin vs. Epinephrine in Cardiac Arrest

Wenzel et al. (2004, n=1,186) found no significant overall survival difference between vasopressin 40 IU and epinephrine for out-of-hospital cardiac arrest. In the asystole subgroup, vasopressin plus epinephrine improved survival to discharge (4.7% vs 1.5%, P=0.04). Subsequent meta-analyses confirmed no meaningful overall benefit, leading to vasopressin's removal from the AHA ACLS algorithm in 2015 [2].

14. Enhanced Safety Profile

Vasopressin has a narrow therapeutic index, and quantitative safety data are essential for informed clinical decision-making.

Ischemic complications (VASST data, n=778). Serious ischemic events occurred in 10.8% of vasopressin patients versus 10.2% of norepinephrine patients (NS). Specific ischemic events included digital ischemia (2.0% vs 1.5%), mesenteric ischemia (0.8% vs 0.5%), myocardial ischemia/infarction (2.6% vs 2.3%), and skin necrosis (0.5% vs 0.3%). Though not significantly different from norepinephrine, the absolute rates highlight the critical importance of dosing within the recommended range [1].

Hyponatremia. During continuous infusion for vasodilatory shock, V2-mediated antidiuresis produces dilutional hyponatremia in approximately 20-35% of patients. In the VASST trial, serum sodium fell below 130 mEq/L in approximately 9% of vasopressin patients during the infusion period. Severe hyponatremia (sodium less than 125 mEq/L) occurred in approximately 3%, warranting regular electrolyte monitoring every 4-6 hours during infusion [1][26].

Arrhythmias. Bradycardia occurs in approximately 5-10% of patients receiving vasopressin for shock, mediated by the baroreceptor reflex response to increased afterload. Ventricular tachyarrhythmias have been reported rarely. Heart block and atrial fibrillation are uncommon but documented [17].

Terlipressin-specific safety (CONFIRM trial, n=300). Respiratory failure occurred in 11% of terlipressin patients versus 2% of placebo patients (P=0.005), primarily due to pulmonary edema from splanchnic-to-systemic fluid redistribution. This finding led to a boxed warning on the terlipressin (Terlivaz) label and contributed to the FDA's initial reluctance to approve the drug [3].

Desmopressin hyponatremic seizures. In the pediatric nocturnal enuresis population, intranasal desmopressin was associated with reports of hyponatremic seizures in children who consumed excessive fluids at bedtime. This risk led to withdrawal of the intranasal formulation for the enuresis indication in multiple countries and mandatory fluid restriction instructions for oral/sublingual formulations [9].

Variceal bleeding complications. At the higher doses used for variceal hemorrhage (0.2-0.8 U/min), side effect-related withdrawal rates approach 25%. Cardiac complications (angina, arrhythmias, myocardial infarction) occur in 10-25% of patients, mesenteric ischemia in 3-8%, and peripheral ischemia in 2-5%. Concurrent nitroglycerin reduces but does not eliminate these risks [19][25].

Rebound hypotension. Abrupt discontinuation of vasopressin infusion after hemodynamic stabilization can cause rebound vasodilation and hypotension. Guidelines recommend gradual tapering at 0.005 U/min per hour after at least 8 hours of hemodynamic stability without catecholamines [11].

15. Related Peptides

See also: Oxytocin, Adrenomedullin, Angiotensin (1-7), Amylin

16. References

1. [1] Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D; VASST Investigators. (2008). Vasopressin versus norepinephrine infusion in patients with septic shock. New England Journal of Medicine. DOI PubMed
2. [2] Wenzel V, Krismer AC, Arntz HR, Sitter H, Stadlbauer KH, Lindner KH; European Resuscitation Council Vasopressor during Cardiopulmonary Resuscitation Study Group. (2004). A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. New England Journal of Medicine. DOI PubMed
3. [3] Wong F, Pappas SC, Curry MP, Reddy KR, Rubin RA, Porayko MK, Gonzalez SA, Mumtaz K, Lim N, Simonetto DA, Sharma P, Sanyal AJ, Mayo MJ, Frederick RT, Escalante S, Jamil K; CONFIRM Study Investigators. (2021). Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. New England Journal of Medicine. DOI PubMed
4. [4] Koshimizu TA, Nakamura K, Egashira N, Hiroyama M, Nonoguchi H, Tanoue A. (2012). Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiological Reviews. DOI PubMed
5. [5] Fenton RA, Knepper MA. (2008). Physiology and pathophysiology of the vasopressin-regulated renal water reabsorption. Pflügers Archiv - European Journal of Physiology. DOI PubMed
6. [6] Morgenthaler NG, Struck J, Alonso C, Bergmann A. (2008). Copeptin: clinical use of a new biomarker. Trends in Endocrinology & Metabolism. DOI PubMed
7. [7] Young LJ, Wang Z. (2006). Vasopressin and pair-bond formation: genes to brain to behavior. Physiology. DOI PubMed
8. [8] Szmydynger-Chodobska J, Chung I, Chodobska A. (2022). Vasopressin and its analogues: from natural hormones to multitasking peptides. International Journal of Molecular Sciences. DOI PubMed
9. [9] Glazener CMA, Evans JHC. (2002). Desmopressin for nocturnal enuresis in children. Cochrane Database of Systematic Reviews. DOI PubMed
10. [10] Kaufmann JE, Vischer UM. (2003). Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). Journal of Thrombosis and Haemostasis. DOI PubMed
11. [11] Cecconi M, Cutuli SL, Antonelli M. (2023). Vasopressin in sepsis and other shock states: state of the art. Journal of Personalized Medicine. DOI PubMed
12. [12] Caldwell HK, Lee HJ, Macbeth AH, Young WS III. (2008). Vasopressin: behavioral roles of an 'original' neuropeptide. Progress in Neurobiology. DOI PubMed
13. [13] Fenske W, Refardt J, Chifu I, Schnyder I, Winzeler B, Drummond J, Ribeiro-Oliveira A Jr, Drescher T, Bilz S, Vogt DR, Malzahn U, Kroiss M, Christ E, Henzen C, Fischli S, Tönjes A, Mueller B, Schopohl J, Flitsch J, Brabant G, Fassnacht M, Christ-Crain M. (2018). A copeptin-based approach in the diagnosis of diabetes insipidus. New England Journal of Medicine. DOI PubMed
14. [14] du Vigneaud V, Ressler C, Trippett S. (1953). The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin. Journal of Biological Chemistry. DOI PubMed
15. [15] du Vigneaud V, Gish DT, Katsoyannis PG. (1954). A synthetic preparation possessing biological properties associated with arginine-vasopressin. Journal of the American Chemical Society. DOI
16. [16] Holmes CL, Patel BM, Russell JA, Walley KR. (2001). Physiology of vasopressin relevant to management of septic shock. Chest. DOI PubMed
17. [17] Barrett LK, Singer M, Clapp LH. (2007). Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Critical Care Medicine. DOI PubMed
18. [18] Maybauer MO, Maybauer DM, Enkhbaatar P, Traber DL. (2008). Physiology of the vasopressin receptors. Best Practice & Research Clinical Anaesthesiology. DOI PubMed
19. [19] Kulkarni AV, Arab JP, Engel B. (2020). Terlipressin has stood the test of time: clinical overview in 2020 and future perspectives. Liver International. DOI PubMed
20. [20] Donaldson ZR, Young LJ. (2008). Oxytocin, vasopressin, and the neurogenetics of sociality. Science. DOI PubMed
21. [21] Morgenthaler NG, Müller B, Struck J, Bergmann A, Redl H, Christ-Crain M. (2007). Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock. DOI PubMed
22. [22] Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL. (2009). Gender and renal function influence plasma levels of copeptin in healthy individuals. Clinical Science. DOI PubMed
23. [23] Kortenoeven MLA, Fenton RA. (2014). Renal aquaporins and water balance disorders. Biochimica et Biophysica Acta. DOI PubMed
24. [24] Bankir L, Bichet DG, Morgenthaler NG. (2017). Vasopressin: physiology, assessment and osmosensation. Journal of Internal Medicine. DOI PubMed
25. [25] Evans RG, Rajapakse NW, Garg S, Gorelik A, Jones MA. (2008). Pharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome. Expert Review of Gastroenterology & Hepatology. DOI PubMed
26. [26] Welt CK, Bhagwat AM, Engel SS, Biller BM, Boepple PA, Leder BZ. (2013). Exogenous vasopressin-induced hyponatremia in patients with vasodilatory shock. Journal of Critical Care. DOI PubMed
27. [27] Leng G, Ludwig M. (2016). Intranasal oxytocin: myths and delusions. Biological Psychiatry. DOI PubMed